BK50164

Cat. No.:	HY-150048
CAS No.:	2204291-78-9
Molecular Formula:	$C_{13}H_{13}ClFN_5O_7$
Molecular Weight:	405.72
Target:	CD73; Apoptosis
Pathway:	Immunology/Inflammation; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BK50164 is a potent CD73 inhibitor with an IC_{50} value of 13.089 μM. BK50164 binds to CD99 with a K_D value of 1.5 μM. BK50164 shows antiproliferative activity. BK50164 induced Apoptosis and cell cycle arrest at Sub-G1 phase[1].
IC_{50} & Target	IC_{50}: 13.089 μM (CD73)[1]

In Vitro

BK50164 (0-400 μM; 48 h) shows antiproliferative activity with IC_{50}s of 35.8, 34.28, 5.17, ≥400, ≥400 μM for A4573, TC-32, TC-71, Saos-2, U-2 OS cells, respectively[2].

BK50164 (4-16 μM; 48 h) induces apoptosis and cell cycle arrest at Sub-G1 phase[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line:	A4573, TC-32, TC-71, Saos-2, U-2 OS cells
Concentration:	0-400 μM
Incubation Time:	48 h
Result:	Inhibited cell viability witn IC_{50}s of 35.8, 34.28, 5.17, ≥400, ≥400 μM for A4573, TC-32, TC-71, Saos-2, U-2 OS cells, respectively.

Cell Cycle Analysis[2]

Cell Line:	TC-32, U-2 OS cells
Concentration:	4, 8, 16 μM
Incubation Time:	48 h
Result:	Induced apoptosis in only TC-32 ES cells but not in U-2 OS cell line and induces cell cycle arrest at Sub-G1 phase.

REFERENCES

[1]. Roland Joseph Billedeau, et al. Ectonucleotidase inhibitors and methods of use thereof. WO2018119284A1.

[2]. Balaraman K, et al. Design, synthesis and biological evaluation of Nucleosidic CD99 inhibitors that selectively reduce Ewing sarcoma viability. Eur J Med Chem. 2023 May 5;251:115244.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA